Maslinic Acid

ID: maslinic_acid

Aliases: olive triterpenoid maslinic acid

Type: compound

Route/form: oral or route depends on studied product

Status: supplement_or_research

Evidence level: human RCT

Best data tier: human controlled/review; exact-use indirect

Support scope: human, non-human/mechanistic

Source types: human_rct, preclinical

Linked sources: 2

Broad outcomes: Cardiovascular / lipids / blood pressure, Muscle growth / performance / recovery

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• exercise-induced soreness
• inflammation
• oxidative stress
• autophagic flux

Optimization domains

• exercise performance
• muscle soreness
• cardiovascular health
• natural product

Research basis

• Randomized human work reports lower soreness/systemic fatigue after marathon or exercise stress, and preclinical work suggests cardiac ischemia-reperfusion protection through autophagic flux.
• A cross-domain triterpenoid worth tracking for recovery and cardiovascular models.

Limits, risks, and missing evidence

• Recovery endpoints are not the same as hypertrophy or ergogenic performance.
• Cardiac protection evidence remains preclinical and disease-model-specific.

Risk flags

• standardization uncertainty
• endpoint specific
• limited replication
• preclinical cardiac claims

Linked papers, labels, and reviews

1. Maslinic acid suppressed early onset muscle soreness and systemic fatigue after full marathon
   human_rct / jstage_maslinic_marathon_2025
   Randomized double-blind placebo-controlled marathon trial.
2. Maslinic acid inhibits myocardial ischemia-reperfusion injury-induced apoptosis and necroptosis
   preclinical / pubmed_maslinic_miri_2022
   Myocardial ischemia-reperfusion/autophagic flux source.